Cancer CDK Inhibitors Sales

Cancer CDK Inhibitors Sales Market Outlook

The global Cancer CDK inhibitors market is projected to reach approximately USD 13.5 billion by 2035, with a compound annual growth rate (CAGR) of around 12.1% during the forecast period from 2025 to 2035. The increasing incidence of cancer globally, along with the rising demand for targeted therapies, is significantly driving market growth. Additionally, advancements in research leading to the development of novel CDK inhibitors are expected to enhance treatment options for cancer patients. The ongoing shift towards personalized medicine is also contributing to the demand for these inhibitors, making them essential components of modern oncology treatment strategies. Furthermore, collaborations between pharmaceutical companies and research institutions are facilitating innovative solutions and accelerating the pace of clinical trials, thereby boosting market expansion.

Growth Factor of the Market

The growth of the cancer CDK inhibitors market can be attributed to several key factors. Firstly, the rise in the prevalence of various cancer types, especially breast and lung cancer, has created a broader patient base requiring effective treatment solutions. Additionally, the increasing awareness regarding early cancer detection and treatment options encourages patients to seek alternatives, including CDK inhibitors, which target specific pathways in cancer cell proliferation. Secondly, the development of combination therapies that enhance the efficacy of CDK inhibitors is becoming more prevalent, allowing oncologists to deliver personalized and effective treatment regimens. Furthermore, significant investments in cancer research by governments and private entities are accelerating the discovery and development of new drugs, including innovative CDK inhibitors. Lastly, favorable regulatory environments and expedited approval processes for breakthrough therapies are boosting the market's growth prospects.

Key Highlights of the Market

• The global Cancer CDK inhibitors market is expected to grow at a CAGR of 12.1% from 2025 to 2035.
• The market is driven by increased prevalence of cancer and demand for targeted therapies.
• Combination therapies are increasingly being utilized to enhance treatment efficacy.
• Significant R&D investments and collaborations are fostering innovation in CDK inhibitor development.
• Favorable regulatory conditions support the rapid development of new cancer therapies.

By Product Type

Palbociclib:

Palbociclib, one of the pioneering CDK inhibitors, has gained substantial attention for its efficacy in treating hormone receptor-positive breast cancer. This drug works by selectively inhibiting CDK4 and CDK6, thus disrupting the cell cycle and preventing cancer cell proliferation. The FDA's approval of Palbociclib ushered in a new era in cancer therapy, particularly for patients with advanced or metastatic breast cancer. As research continues to expand on its use in combination with hormonal therapies, Palbociclib's market share is projected to increase, further solidifying its position as a cornerstone treatment option in oncology.

Ribociclib:

Ribociclib is another significant CDK inhibitor that operates similarly to Palbociclib but has unique properties that may offer different therapeutic advantages. Approved by regulatory agencies, Ribociclib is primarily indicated for postmenopausal women with HR-positive, HER2-negative advanced breast cancer. Clinical trials have shown promising results in terms of progression-free survival when combined with aromatase inhibitors. The drug's favorable safety profile and relatively manageable side effects make it an attractive option for oncologists and patients alike, potentially leading to increased adoption and market growth.

Abemaciclib:

Abemaciclib distinguishes itself by being an oral CDK inhibitor that can be utilized as monotherapy or in combination with other endocrine therapies for the treatment of HR-positive breast cancer. Its unique mechanism of action allows for less dependency on specific treatment regimens, making it suitable for a wider range of patients. Ongoing research into Abemaciclib's effectiveness in various cancer types, coupled with its promising clinical outcomes, is likely to drive its adoption in oncology practices, thereby enhancing its market presence.

Lerociclib:

Lerociclib is an emerging player in the CDK inhibitor market, currently under investigation for its potential to treat various malignancies, particularly HR-positive breast cancer. Preliminary studies suggest that Lerociclib exhibits a favorable safety profile and may offer an effective oral administration route, which is appealing to many patients. As clinical trials continue to explore its effectiveness and safety, Lerociclib is poised to capture a segment of the market, especially as personalized medicine becomes more prevalent in treatment protocols.

Others:

This category includes various investigational and less widely recognized CDK inhibitors that are in different stages of research and development. These inhibitors may target additional cyclin-dependent kinases or utilize novel mechanisms to combat cancer. The ongoing exploration and validation of these products could lead to breakthroughs in oncology, as they may offer alternative options for patients who do not respond to existing therapies. The “Others” segment is critical in fostering innovation and expanding the overall therapeutic landscape for cancer treatment.

By Application

Breast Cancer:

Breast cancer remains one of the primary applications driving the demand for CDK inhibitors. With the increasing incidence of breast cancer, particularly among women, there is a growing need for effective treatment options. CDK inhibitors, such as Palbociclib and Ribociclib, have shown significant efficacy in treating HR-positive breast cancer, leading to their rapid adoption in clinical settings. The availability of targeted therapies has not only improved patient outcomes but also has contributed to the overall growth of the cancer CDK inhibitor market. Furthermore, ongoing research into combination therapies is likely to expand treatment options for breast cancer patients, enhancing the market potential.

Lung Cancer:

Lung cancer is another critical application area for CDK inhibitors, particularly as research continues to uncover the potential of these drugs in treating various lung cancer subtypes. While traditionally more associated with breast cancer, recent studies have begun to explore the efficacy of CDK inhibitors in lung adenocarcinoma and squamous cell carcinoma. The introduction of effective treatment strategies for lung cancer patients is crucial, given the high mortality rates associated with this disease. The market for CDK inhibitors in lung cancer remains relatively untapped, presenting a significant growth opportunity as more clinical data becomes available proving their effectiveness.

Colorectal Cancer:

Colorectal cancer is increasingly being recognized as a potential application for CDK inhibitors, particularly as the understanding of molecular pathways involved in its progression grows. The ability of CDK inhibitors to disrupt cell cycle regulation may provide a complementary approach to existing treatment modalities. As ongoing clinical trials evaluate the safety and efficacy of CDK inhibitors in colorectal cancer, it is expected that the market will see a gradual increase as data supports their role in enhancing treatment outcomes for patients diagnosed with this aggressive cancer.

Leukemia:

The application of CDK inhibitors in leukemia is an emerging area of interest. Preclinical studies have indicated that CDK inhibition may have a beneficial effect on leukemic cells, leading to further exploration in clinical trials. Given the complexities of leukemia treatment and the need for innovative approaches, CDK inhibitors could potentially offer new therapeutic strategies. As research continues, the market for CDK inhibitors in leukemia may witness significant growth, driven by the demand for effective therapies in this challenging area of oncology.

Others:

This segment encompasses various other cancers where CDK inhibitors may play a role, including pancreatic, prostate, and ovarian cancers. As research progresses, particularly in understanding the molecular mechanisms of cancer development, the potential applications of CDK inhibitors are likely to expand. The “Others” category is vital in exploring uncharted territories in cancer treatment, highlighting the versatility and adaptability of CDK inhibitors beyond their initial indications. This exploration may lead to the development of new treatment guidelines and further adoption of these inhibitors in oncology.

By Distribution Channel

Hospitals:

Hospitals represent a key distribution channel for cancer CDK inhibitors, as they are often the first point of care for patients diagnosed with cancer. Oncologists in these settings typically have access to the latest treatment options and can prescribe CDK inhibitors as part of therapeutics regimens. The hospital setting allows for comprehensive patient care, facilitating treatment administration and monitoring for potential side effects. As the prevalence of cancer continues to rise, the demand for CDK inhibitors within hospitals is expected to grow steadily, with hospitals adapting to integrate new therapies into their oncology departments.

Cancer Research Centers:

Cancer research centers play a crucial role in the distribution of CDK inhibitors due to their focus on clinical trials and innovative therapies. These centers often collaborate with pharmaceutical companies to investigate new treatment modalities and evaluate the effectiveness of CDK inhibitors in various cancer types. As the research continues to unveil new applications for these inhibitors, cancer research centers serve as vital hubs for education, patient recruitment, and the advancement of treatment protocols. The impact of these centers on the market cannot be understated, as they pave the way for future developments and establish best practices in cancer treatment.

Retail Pharmacies:

Retail pharmacies are an essential distribution channel for cancer CDK inhibitors, especially for patients transitioning from hospital-based care to outpatient therapy. Patients often require refills of their medications and can conveniently access these treatments at retail pharmacies. The increasing acceptance of oral therapies such as CDK inhibitors within outpatient settings has also encouraged pharmacies to stock these medications more widely. As the patient population continues to grow, retail pharmacies are likely to see increased demand for cancer treatments, including CDK inhibitors, making them crucial players in the distribution landscape.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for cancer CDK inhibitors, particularly in the wake of the COVID-19 pandemic, which accelerated the adoption of telemedicine and online pharmaceutical services. These digital platforms offer convenience and accessibility for patients seeking to procure their medications without the need for in-person visits. The ability to obtain prescriptions for CDK inhibitors online can enhance adherence to treatment regimens, especially for individuals managing chronic health conditions. As the trend towards e-commerce in healthcare continues, online pharmacies are poised to capture a growing share of the market for cancer treatments.

Others:

This category includes various distribution channels such as specialty pharmacies and mail-order services that cater specifically to oncology patients. These channels often offer personalized services, including medication management and patient education regarding side effects and adherence. The role of these alternative distribution methods is increasingly important as more patients seek tailored support in their cancer treatment journey. As awareness grows regarding the availability of CDK inhibitors, these channels could see an uptick in demand, contributing to the overall market dynamics.

By Ingredient Type

Chemical-Based Inhibitors:

Chemical-based CDK inhibitors form the backbone of the current therapeutic strategies targeting cancer. These inhibitors are synthesized through complex chemical processes to selectively inhibit cyclin-dependent kinases involved in the regulation of the cell cycle. The majority of CDK inhibitors approved for clinical use, such as Palbociclib and Ribociclib, fall into this category. Their efficacy has been well-documented through extensive clinical trials, and ongoing research continues to optimize their formulations and combinations with other therapies, enhancing patient outcomes across various cancer types.

Herbal-Based Inhibitors:

Herbal-based CDK inhibitors represent a novel approach to cancer treatment, often derived from traditional medicinal systems. These natural compounds are being studied for their potential to modulate cell cycle proteins and exhibit anti-cancer properties. While still in the experimental stages, herbal-based inhibitors show promise as complementary therapies alongside chemical agents, potentially reducing side effects and improving patient quality of life. As more research validates their efficacy, herbal-based CDK inhibitors could carve out a niche in the oncology market, appealing to patients seeking holistic treatment options.

Protein-Based Inhibitors:

Protein-based CDK inhibitors are an emerging class of therapeutics that focus on utilizing engineered proteins to inhibit cyclin-dependent kinases. These inhibitors have the potential to provide targeted therapy with fewer side effects compared to traditional chemical agents. Research is ongoing to understand the full scope of their applications in oncology, and initial results have been promising. As investigations expand, protein-based inhibitors may offer new strategies for treating patients who have developed resistance to existing therapies, enhancing their viability within the cancer treatment landscape.

RNA-Based Inhibitors:

RNA-based CDK inhibitors represent a cutting-edge approach to cancer treatment by leveraging the specificity of RNA interference to inhibit the expression of cyclin-dependent kinases at the genetic level. This innovative strategy has garnered interest due to its potential for high specificity and reduced off-target effects. While still largely in the research phase, RNA-based inhibitors could revolutionize cancer therapeutics by providing a new mechanism for targeting cell cycle regulation. As scientific understanding of RNA biology grows, the introduction of RNA-based CDK inhibitors could significantly impact treatment outcomes in oncology.

Others:

This category includes various investigational compounds and novel formulations that do not fit into the established ingredient types. As research in cancer therapy evolves, new formulations and hybrid approaches may emerge that combine elements from multiple types of inhibitors. The exploration of “Others” ensures that the market remains dynamic and responsive to advances in cancer research, potentially leading to breakthroughs in treatment strategies that significantly improve patient outcomes.

By Region

The North American cancer CDK inhibitors market is expected to dominate the global landscape, accounting for nearly 40% of the market share by 2035. The presence of key pharmaceutical companies, advanced healthcare infrastructure, and robust investment in cancer research and development significantly contribute to this dominance. The region is home to several leading CDK inhibitors approved for clinical use, and the increasing focus on personalized medicine is likely to further drive market growth. The CAGR for North America is anticipated to be around 13.5%, reflecting the region's strong commitment to advancing cancer treatment options and improving patient care.

In Europe, the cancer CDK inhibitors market is also expected to witness substantial growth, contributing approximately 30% to the global market by 2035. The European market is driven by factors such as the rising incidence of cancer and a growing emphasis on innovative therapies. Countries like Germany, France, and the UK are leading in terms of market size, supported by favorable regulatory frameworks and initiatives aimed at enhancing patient access to cutting-edge therapies. The CAGR for Europe is projected at approximately 11.7%, highlighting the region's active role in cancer research and the adoption of targeted therapies in clinical settings.

Opportunities

The cancer CDK inhibitors market presents numerous opportunities for growth, particularly as ongoing research and development efforts aim to expand the clinical applications of these drugs. One significant opportunity lies in the exploration of combination therapies, where CDK inhibitors are used alongside other treatments such as immunotherapy and targeted agents. This approach not only enhances the therapeutic efficacy but also addresses potential resistance mechanisms, improving patient outcomes. Pharmaceutical companies can capitalize on this trend by investing in clinical trials that evaluate the safety and efficacy of such combinations, laying the groundwork for new treatment protocols and guidelines that integrate CDK inhibitors into standard oncology practices.

Furthermore, geographical expansion into emerging markets presents another avenue for growth. As healthcare infrastructure improves and access to advanced cancer therapies increases in regions like Asia Pacific and Latin America, there is a rising demand for effective cancer treatments, including CDK inhibitors. Companies that strategically enter these markets, potentially through partnerships or collaborations with local healthcare providers, can tap into a burgeoning patient population needing innovative therapies. The focus on education, awareness, and access to cancer care will be crucial in translating these opportunities into tangible market growth.

Threats

Despite the promising outlook for the cancer CDK inhibitors market, several threats could impede growth. One significant concern is the emergence of generic alternatives as patents for leading CDK inhibitors expire. The availability of cost-effective generics could potentially reduce market shares for branded products, impacting revenue for companies that have heavily invested in research and development. Additionally, the increasing competition from alternative cancer therapies, including immunotherapy and targeted agents, can shift treatment paradigms and potentially limit the market's growth for CDK inhibitors. Companies must remain vigilant and adaptable in their strategies to counteract these competitive pressures to maintain their market positions.

Another pressing threat comes from regulatory challenges that can delay the approval and commercialization of new CDK inhibitors. The stringent requirements for clinical trials and the need for substantial evidence of safety and efficacy can prolong the development timelines for new therapies. In an ever-evolving oncology landscape, the ability to rapidly bring drugs to market is essential, and any delays can hinder a company's competitiveness. Therefore, navigating regulatory complexities and ensuring compliance while expediting drug development processes will be critical for companies operating in this space.

Competitor Outlook

• Pfizer Inc.
• Novartis AG
• Roche Holding AG
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Incyte Corporation
• Sanofi S.A.
• Exelixis, Inc.
• Merck & Co., Inc.
• Janssen Pharmaceuticals (Johnson & Johnson)
• AbbVie Inc.
• Seattle Genetics, Inc.
• Akoya Biosciences, Inc.
• Celgene Corporation (a Bristol Myers Squibb Company)

The competitive landscape of the Cancer CDK inhibitors market is characterized by a mix of established pharmaceutical giants and emerging biotech companies. Key players in this market are investing heavily in research and development to create innovative therapies that cater to the growing needs of oncology practitioners and patients. Pfizer, for instance, has made significant advancements with its CDK inhibitor offerings and continues to explore combination therapies to enhance treatment efficacy. Similarly, Novartis and Roche are also leading the charge with their respective pipelines, focusing on providing targeted solutions that address the unique challenges of cancer treatment.

Furthermore, companies like Eli Lilly and Amgen are leveraging their expertise in biotechnology to develop next-generation CDK inhibitors that promise improved efficacy and safety profiles. Their ongoing clinical trials aim to evaluate these new compounds, which could position them favorably in the competitive landscape. The aggressive pursuit of innovation and a robust pipeline of investigational products among these key players emphasize the dynamic nature of this market, where staying ahead of the curve is crucial to maintaining a competitive edge.

Emerging companies, such as Incyte and Exelixis, are also making their mark by focusing on niche segments within the CDK inhibitors market. These companies often take innovative approaches to drug development, utilizing advanced technologies and research methodologies to bring novel treatments to patients. Their agility and ability to adapt to market changes allow them to carve out a distinct space in the industry. As the competitive landscape evolves, collaborations and partnerships among established and emerging players will play a pivotal role in shaping the future of cancer treatment.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Exelixis, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Incyte Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gilead Sciences Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Eli Lilly and Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Seattle Genetics, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Akoya Biosciences, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Janssen Pharmaceuticals (Johnson & Johnson)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Celgene Corporation (a Bristol Myers Squibb Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Cancer CDK Inhibitors Sales Market, By Application
    • 6.1.1 Breast Cancer
    • 6.1.2 Lung Cancer
    • 6.1.3 Colorectal Cancer
    • 6.1.4 Leukemia
    • 6.1.5 Others
  • 6.2 Cancer CDK Inhibitors Sales Market, By Product Type
    • 6.2.1 Palbociclib
    • 6.2.2 Ribociclib
    • 6.2.3 Abemaciclib
    • 6.2.4 Lerociclib
    • 6.2.5 Others
  • 6.3 Cancer CDK Inhibitors Sales Market, By Ingredient Type
    • 6.3.1 Chemical-Based Inhibitors
    • 6.3.2 Herbal-Based Inhibitors
    • 6.3.3 Protein-Based Inhibitors
    • 6.3.4 RNA-Based Inhibitors
    • 6.3.5 Others
  • 6.4 Cancer CDK Inhibitors Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Cancer Research Centers
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Cancer CDK Inhibitors Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Cancer CDK Inhibitors Sales market is categorized based on

By Product Type

• Palbociclib
• Ribociclib
• Abemaciclib
• Lerociclib
• Others

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Leukemia
• Others

By Distribution Channel

• Hospitals
• Cancer Research Centers
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Chemical-Based Inhibitors
• Herbal-Based Inhibitors
• Protein-Based Inhibitors
• RNA-Based Inhibitors
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Novartis AG
• Roche Holding AG
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Incyte Corporation
• Sanofi S.A.
• Exelixis, Inc.
• Merck & Co., Inc.
• Janssen Pharmaceuticals (Johnson & Johnson)
• AbbVie Inc.
• Seattle Genetics, Inc.
• Akoya Biosciences, Inc.
• Celgene Corporation (a Bristol Myers Squibb Company)